NBRI Clinical Research

Brain scan

NBRI clinical research is helping us provide pregnant woman with new diagnostic information and fetal treatment options. We've found safe new ways to perform MRI scans on newborn babies, develop lifesaving procedures and better detect brain abnormalities. We have several currently active research studies:

MOM's Study (Management Of Myelomeningocele Study)

This study is part of a National Institutes of Health (NIH) sponsored randomized clinical trial in cooperation with the UCSF Fetal Treatment Center to examine the best treatment option for these fetuses with Myelomeningocele, a form of Spina Bifida. Trial patients are randomized to receive either fetal surgery or care and surgery after birth.

Learn more about the MOM's Study

PREMRI Study

Our primary goal is to see if we can identify a relationship between the findings on a prematurely born baby’s MRI scan and his or her long term neurological and developmental outcome. If we have a better way of understanding the injury and predicting outcome, we can do a better job planning treatment for babies and determining who would be good candidates for early therapies.

Learn more about the PREMRI Study

BAMRI Study

This study uses MRI to assess possible possible brain injury in babies that may have suffered from lack of oxygen supply to the brain around the time of birth. We are finding ways to assess how newborns' brains get injured and what the best diagnostic tools are to see that injury early on. Our aim is to see brain injury early enough so we can develop treatments to reduce the damage. We also hope to identify those children whose long-term development will be affected, and who could benefit from early therapy.

Learn more about the BAMRI Study

PMD Clinical Trial

This Phase I study will assess the safety and tolerance of purified human central nervous system stem cells (HuCNS-SC® cells) transplanted in patients with Pelizaeus-Merzbacher Disease (PMD), a rare disorder in which the brain profoundly lacks myelin, an insulating substance for nerve cells which is critical for their ability to communicate with other nerve cells.

For more information please visit the PMD Clinical Trial.

This trial is closed for enrollment. If you are interested in this trial please email [email protected].